Results 1 to 10 of about 138,032 (344)
Expert Review of Hematology, 2021 Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count (
Bussel J. +4 more
+7 more sources
New England Journal of Medicine, 2019 This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors’ clinical recommendations.
Cooper, Nichola, Ghanima, Waleed Khalid
+7 more sources
Success of Helicobacter pylori Eradication Therapy and Long Lasting Platelet Recovery in an Iranian Patient with Severe Immune Thrombocytopenia [PDF]
Journal of Kerman University of Medical Sciences, 2021 Background: Helicobacter pylori is a gram-negative spirochete that usually affects the gastric mucosa and has a prevalence of more than 50% of people worldwide.
Esmaeil Shahabi Satlsar +5 more
doaj +1 more source
Hematology, 2013 Immune thrombocytopenia (ITP) is a common hematologic disorder characterized by isolated thrombocytopenia. ITP presents as a primary or a secondary form. ITP may affect individuals of all ages, with peaks during childhood and in the elderly, in whom the age-specific incidence of ITP is greatest. Bleeding is the most common clinical manifestation of ITP.
Gaurav, Kistangari, Keith R, McCrae
openaire +4 more sources
COVID-19-associated immune thrombocytopenia [PDF]
Romanian Journal of Infectious Diseases, 2021 The coronavirus disease 2019 (COVID-19) is a contagious respiratory tract infection caused by the betacoronavirus SARS-CoV-2. The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020.
Mara-Andrada Plesu +4 more
doaj +1 more source
Understanding Immune Thrombocytopenia: Looking Out of the Box
Frontiers in Medicine, 2021 The pathogenesis of immune thrombocytopenia (ITP) is increasingly being elucidated, and its etiology is becoming more frequently identified, leading to a diagnostic shift from primary to secondary ITP.
Alexandra Schifferli +8 more
doaj +1 more source
Treatment of drug-induced immune thrombocytopenias
Haematologica, 2022 Several therapeutic agents can cause thrombocytopenia by either immune-mediated or non-immune-mediated mechanisms. Non-immune-mediated thrombocytopenia is due to direct toxicity of drug molecules to platelets or megakaryocytes.
Irene Marini +3 more
doaj +1 more source
Hematology, 2010 Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmune-mediated platelet destruction and impairment of thrombopoiesis. ITP may occur in the absence of an evident predisposing etiology (primary ITP) or secondary to a growing list of associated conditions (secondary ITP), and must be differentiated from ...
Adam, Cuker, Douglas B, Cines
openaire +2 more sources
Critical Care Explorations, 2021 OBJECTIVES:. The development of thrombocytopenia and thrombosis after the administration of the AstraZeneca and Johnson & Johnson/Janssen vaccines has been recently described.
Luca Zazzeron, MD +3 more
doaj +1 more source
SAGE Open Medicine, 2023 Background: Platelet count and bleeding risk are frequently used in clinical assessments of the severity of immune thrombocytopenia. On the other hand, immune thrombocytopenia also influences patients’ health-related quality of life.
Dessale Abate Beyene +3 more
doaj +1 more source